Companies › Shandong Suncadia Medicine
19 active drug programs in 40 registered trials: 18 Phase 2, 15 Phase 1, 7 Phase 3; Oncology, Cardiovascular, Metabolic and endocrine, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HRS-1780 Tablets Aldosterone synthase inhibitor | – | Phase 3 | Chronic Kidney Disease; Primary Aldosteronism; Uncontrolled or Resistant Hypertension | Nov 2026 |
| HRS-1893 Cardiac myosin inhibitor | – | Phase 3 | Obstructive Hypertrophic Cardiomyopathy; Heart Failure With Preserved Ejection Fraction; Hypertrophic Cardiomyopathy | Nov 2026 |
| HRS-7535 | – | Phase 3 | Hypertension With Overweight or Obesity; Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity | Dec 2026 |
| HRS-8080 CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Locally Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Unresectable or Metastatic Breast Cancer … | Dec 2026 |
| HRS-2129 | – | Phase 2 | Postoperative Analgesia; Acute Gouty Arthritis; Diabetic Peripheral Neuropathic Pain | Nov 2026 |
| Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Advanced Malignant Tumour | Dec 2026 |
| HRS-7058 KRAS G12C selective inhibitor | KRAS | Phase 2 | Advanced Malignant Tumour; Solid Tumors; Pancreatic Cancer | Dec 2026 |
| HRS-7085 | – | Phase 2 | Adult Patients With Moderately to Severely Active Ulcerative Colitis | Dec 2026 |
| SHR-1826 | – | Phase 2 | Advanced Malignant Tumour | Dec 2026 |
| SHR-9839 | – | Phase 2 | Advanced Malignant Tumour | Dec 2026 |
| SHR-A1202 | – | Phase 2 | Advanced Malignant Tumour | Dec 2026 |
| HRS-1301 | – | Phase 2 | Hyperlipidemia | – |
| HRS-1358 | – | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Dec 2026 |
| HRS-2189 | – | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Dec 2026 |
| HRS-6209 | – | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer; Advanced Unresectable or Metastatic Breast Cancer of Adults | Dec 2026 |
| HRS-6208 | – | Phase 1 | Solid Tumors; Advanced Unresectable or Metastatic Breast Cancer of Adults | Aug 2027 |
| HRS-6719 MTAP inhibitor | – | Phase 1 | Advanced/Metastatic Solid Tumors | Dec 2027 |
| HRS-3802 | – | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| HRS-7156 | – | Phase 1 | Heart Failure | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06516068 | HRS-1893 | Phase 2 | Obstructive Hypertrophic Cardiomyopathy | Cardiovascular | Nov 2024 |
| NCT07185594 | HRS-2129 | Phase 2 | Postoperative Analgesia | Other | Dec 2025 |
| NCT06167694 | HRS-8080 | Phase 1 | Unresectable or Metastatic Breast Cancer | Oncology | Jun 2026 |
| NCT06167694 | HRS-8080 | Phase 1 | Unresectable or Metastatic Breast Cancer | Oncology | Jun 2026 |
| NCT06383871 | HRS-7058 | Phase 1 | Advanced Malignant Tumour | Oncology | Jun 2026 |
| NCT07229937 | HRS-1301 | Phase 2 | Hyperlipidemia | Metabolic and endocrine | Aug 2026 |
| NCT07601087 | HRS-7156 | Phase 1 | Heart Failure | Cardiovascular | Sep 2026 |
| NCT07470983 | HRS-1780 Tablets | Phase 2 | Primary Aldosteronism | Metabolic and endocrine | Nov 2026 |
| NCT07021976 | HRS-1893 | Phase 3 | Obstructive Hypertrophic Cardiomyopathy | Cardiovascular | Nov 2026 |
| NCT07706777 | HRS-2129 | Phase 2 | Acute Gouty Arthritis | Immunology | Nov 2026 |
| NCT07377721 | HRS-2129 | Phase 1 | Diabetic Peripheral Neuropathic Pain | Neurology | Nov 2026 |
| NCT06820099 | HRS-7535 | Phase 2 | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity | Cardiovascular | Dec 2026 |
| NCT06915142 | HRS-7058 | Phase 2 | Advanced Malignant Tumour | Oncology | Dec 2026 |
| NCT07229950 | HRS-7085 | Phase 2 | Adult Patients With Moderately to Severely Active Ulcerative Colitis | Immunology | Dec 2026 |
| NCT06915142 | SHR-1826 | Phase 2 | Advanced Malignant Tumour | Oncology | Dec 2026 |
| NCT06915142 | SHR-A1202 | Phase 2 | Advanced Malignant Tumour | Oncology | Dec 2026 |
| NCT06915142 | Bevacizumab (BP102) | Phase 2 | Advanced Malignant Tumour | Oncology | Dec 2026 |
| NCT06915142 | SHR-9839 | Phase 2 | Advanced Malignant Tumour | Oncology | Dec 2026 |
| NCT06679036 | HRS-2189 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT06679036 | HRS-8080 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT06679036 | HRS-6209 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT06679036 | HRS-1358 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT07269717 | HRS-1893 | Phase 2 | Heart Failure With Preserved Ejection Fraction | Cardiovascular | Mar 2027 |
| NCT07032077 | HRS-7058 | Phase 2 | Solid Tumors | Oncology | Jun 2027 |
| NCT07024173 | HRS-8080 | Phase 3 | Locally Advanced Breast Cancer | Oncology | Aug 2027 |
| NCT06727812 | HRS-6208 | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
| NCT07125950 | HRS-8080 | Phase 2 | Advanced Breast Cancer | Oncology | Sep 2027 |
| NCT07528027 | HRS-7535 | Phase 3 | Hypertension With Overweight or Obesity | Cardiovascular | Dec 2027 |
| NCT07021963 | HRS-1893 | Phase 2 | Hypertrophic Cardiomyopathy | Cardiovascular | Dec 2027 |
| NCT06922357 | HRS-6719 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Dec 2027 |
| NCT07354022 | HRS-8080 | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Oncology | Dec 2028 |
| NCT07354022 | HRS-8080 | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Oncology | Dec 2028 |
| NCT07389733 | HRS-8080 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer of Adults | Oncology | Dec 2028 |
| NCT07389733 | HRS-6209 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer of Adults | Oncology | Dec 2028 |
| NCT07389733 | HRS-6208 | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer of Adults | Oncology | Dec 2028 |
| NCT06770569 | HRS-3802 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07589569 | HRS-7058 | Phase 2 | Pancreatic Cancer | Oncology | Dec 2028 |
| NCT07708441 | HRS-1780 Tablets | Phase 2 | Uncontrolled or Resistant Hypertension | Cardiovascular | Apr 2029 |
| NCT07419828 | HRS-1780 Tablets | Phase 3 | Chronic Kidney Disease | Genitourinary | Apr 2030 |
| NCT07349069 | HRS-8080 | Phase 3 | Breast Cancer | Oncology | Dec 2030 |
Shanghai Hengrui Pharmaceutical Jiangsu Simcere Pharmaceutical Shanghai Henlius Biotech Akeso Sichuan Baili Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.